Annovis Bio, Inc. (ANVS) Stock
ANVS Key Statistics
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
CEO: Maria L. Maccecchini. Company website
ANVS — Frequently Asked Questions
What is the ANVS stock price today?
Annovis Bio, Inc. (ANVS) trades at $1.62, down 29.57% on the day, as of Sep 20, 2026 15:01 UTC.
What is Annovis Bio, Inc.'s market cap?
Annovis Bio, Inc. has a market capitalisation of $31.87M, calculated from the live ANVS share price and shares outstanding.
What is the P/E ratio of ANVS?
ANVS has no meaningful price-to-earnings ratio: Annovis Bio, Inc. lost $1.54 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Annovis Bio, Inc. make?
Annovis Bio, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ANVS?
ANVS has traded between $1.61 and $3.03 over the past 52 weeks, and the last price is 46.5% below that high.
Is Annovis Bio, Inc. profitable?
Yes. Annovis Bio, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ANVS?
Wall Street analysts rate ANVS Buy, with an average price target of $25.67, 1,484.6% above the current price.
What sector is Annovis Bio, Inc. in?
Annovis Bio, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Annovis Bio, Inc.?
Maria L. Maccecchini is the chief executive of Annovis Bio, Inc., which employs 8 people.
Where can I track ANVS in real time?
QFI Terminal shows ANVS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ANVS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ANVS in Terminal See plans